Literature DB >> 29959811

Hemoglobin A1c predicts hemorrhagic transformation and poor outcomes after acute anterior stroke.

G Zhang1, M He1, Y Xu2, X Li3, Z Cai1, Z Guo1, P Meng1, N Ji1, X He1, L Pang1.   

Abstract

BACKGROUND AND
PURPOSE: Hemorrhagic transformation (HT) is a major complication of acute ischaemic stroke that is potentially related to clinical deterioration. The objective of this study was to assess whether chronic hyperglycemia is a predictive factor of HT in patients with acute anterior stroke.
METHODS: Patients with acute anterior stroke were included in this study. Hemoglobin A1c (HbA1c) was measured in the morning after hospitalization. HT was detected by computed tomography scans or gradient echo magnetic resonance imaging performed 4 (±2) days after onset. Univariate and multivariate logistic regression analyses were used to assess the risks for HT and short-term outcomes.
RESULTS: Of the 426 patients included, 93 (21.8%) had HT: 61 (14.3%) presented with hemorrhagic infarction and 32 (7.5%) presented with parenchymal hematoma. A total of 54 patients received thrombolytic treatment and 18 (33.3%) were found to have HT. In the multivariate analysis, HbA1c [odds ratio (OR), 1.294; 95% confidence interval (CI), 1.097-1.528], infarction size (OR, 3.358; 95% CI, 1.748-6.449) and thrombolytic therapy (OR, 3.469; 95% CI, 1.757-6.847) were predictors of HT. The predictive effect of HbA1c on HT was still observed in both groups when patients were stratified according to the levels of fasting blood glucose. HbA1c was found to be a predictor of poor outcomes in the multilogistic regression analysis (OR, 1.482; 95% CI, 1.228-1.788).
CONCLUSIONS: Higher HbA1c was independently related to HT and poor neurological outcomes in patients with ischaemic stroke. These findings have significant implications for the treatment of diabetes and glucose management in patients with diabetes mellitus and/or acute ischaemic stroke.
© 2018 EAN.

Entities:  

Keywords:  hemoglobin A1c; hemorrhagic transformation; hyperglycemia; outcome; stroke

Mesh:

Substances:

Year:  2018        PMID: 29959811     DOI: 10.1111/ene.13747

Source DB:  PubMed          Journal:  Eur J Neurol        ISSN: 1351-5101            Impact factor:   6.089


  6 in total

Review 1.  Hemorrhagic Transformation in Ischemic Stroke and the Role of Inflammation.

Authors:  Elena Spronk; Gina Sykes; Sarina Falcione; Danielle Munsterman; Twinkle Joy; Joseph Kamtchum-Tatuene; Glen C Jickling
Journal:  Front Neurol       Date:  2021-05-14       Impact factor: 4.003

2.  Low triiodothyronine syndrome is associated with hemorrhagic transformation in patients with acute ischaemic stroke.

Authors:  Gui-Qian Huang; Ya-Ying Zeng; Qian-Qian Cheng; Hao-Ran Cheng; Yi-Ting Ruan; Cheng-Xiang Yuan; Yun-Bin Chen; Wei-Lei He; Hui-Jun Chen; Jin-Cai He
Journal:  Aging (Albany NY)       Date:  2019-08-27       Impact factor: 5.682

3.  Hemostasis functions are associated with hemorrhagic transformation in non-atrial fibrillation patients: a case-control study.

Authors:  Hao-Ran Cheng; Yun-Bin Chen; Ya-Ying Zeng; Yi-Ting Ruan; Cheng-Xiang Yuan; Qian-Qian Cheng; Hui-Jun Chen; Xiao-Qian Luan; Gui-Qian Huang; Jin-Cai He
Journal:  BMC Neurol       Date:  2021-01-26       Impact factor: 2.474

4.  Glycated Hemoglobin as a Marker for Predicting Outcomes of Patients With Stroke (Ischemic and Hemorrhagic): A Systematic Review and Meta-Analysis.

Authors:  Yaya Bao; Dadong Gu
Journal:  Front Neurol       Date:  2021-03-31       Impact factor: 4.003

5.  Association Between Raised HbA1c Levels and Hemorrhagic Transformation in Patients With Ischemic Stroke.

Authors:  Benish Afzal; Syed Ahsan Ali; Bushra Jamil
Journal:  Cureus       Date:  2021-11-27

6.  High glycemic albumin representing prestroke glycemic variability is associated with hemorrhagic transformation in patients receiving intravenous thrombolysis.

Authors:  Sang-Hwa Lee; Min Uk Jang; Yerim Kim; So Young Park; Chulho Kim; Yeo Jin Kim; Jong-Hee Sohn
Journal:  Sci Rep       Date:  2022-01-12       Impact factor: 4.379

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.